ABSTRACT
The excruciating process of developing the nonclassic growth hormone (GH) secretagogues (GHS) in the early 1980s was guided by the in vitro GH-releasing capabilities of the synthetic compounds (1). with this selective process, peptides that were able to release GH in vivo, but were scarcely effective in vitro were discarded, a process that favored the selection of compounds for which the action was mainly at the pituitary level. Interestingly, cumulative evidence suggests that GHSs also act at a central, probably hypothalamic site, and that this alternative point of activation is as relevant as the pituitary one.
